Homegrown biotech Bharat Biotech said on Saturday that it is on track to achieve the goal of mobilizing around 26,000 volunteers across the country for the Phase III clinical trial of its vaccine Kovaxin of Kovid-19.
The company said that 23 thousand volunteers have already joined it for testing. The company's statement comes after an expert committee of the Central Medicines Authority of India recommended the approval of limited use of covaxine in an emergency.
This recommendation for the Bharat Biotech vaccine was made a day after the Serum Institute of India approved the application of the emergency use of the vaccine Kovishield of Oxford-AstraZeneca.
Bharat Biotech, Serum Institute, and Pfizer applied to the Drug Controller General of India (DCGI) for approval for the emergency use of their respective vaccines.